Accolade (NASDAQ:ACCD – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.13, Briefing.com reports. Accolade had a negative return on equity of 22.53% and a negative net margin of 24.09%. The business had revenue of $110.50 million during the quarter, compared to the consensus estimate of $105.22 million. During the same period in the previous year, the company posted ($0.52) earnings per share. The business’s revenue for the quarter was up 18.6% on a year-over-year basis. Accolade updated its FY 2025 guidance to EPS and its Q2 2025 guidance to EPS.
Accolade Stock Performance
NASDAQ ACCD opened at $3.71 on Friday. The business’s 50-day moving average price is $7.20 and its 200 day moving average price is $9.70. Accolade has a twelve month low of $3.70 and a twelve month high of $15.36. The company has a market capitalization of $296.84 million, a PE ratio of -4.80 and a beta of 2.10. The company has a current ratio of 2.64, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47.
Insider Transactions at Accolade
In other news, CAO Colin Mchugh sold 5,543 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $6.62, for a total value of $36,694.66. Following the transaction, the chief accounting officer now directly owns 50,177 shares in the company, valued at approximately $332,171.74. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold a total of 14,746 shares of company stock worth $104,586 in the last three months. 8.30% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Check Out Our Latest Analysis on Accolade
Accolade Company Profile
Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.
Read More
- Five stocks we like better than Accolade
- What is a buyback in stocks? A comprehensive guide for investors
- Nike Stock Falls to Bargain Basement After Analysts Slash Targets
- Which Wall Street Analysts are the Most Accurate?
- Tesla Stock’s Comeback Rally Has Officially Started
- What is Put Option Volume?
- Albemarle Stock: Strong Fundamentals vs. Lithium Volatility
Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter.